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Summary 
The Norwegian Scientific Committee for Food Safety (VKM) has appointed an ad hoc-group 
of experts to answer a request from the Norwegian Food Safety Authority regarding benefit 
and risk assessment of Lactobacillus paracasei ssp. paracasei F19 (F19) in processed cereal-
based baby foods intended for small children 1-3 years. This assessment is based on the 
literature provided by the notifier as well as that found by a MEDLINE search.  
A notification regarding two products of processed cereal-based baby foods (hereafter called 
cereals), intended for small children and supplemented with the bacterium F19 initiated this 
work.  
A daily supply of a monoculture of a particular bacterial strain in large quantities to an age 
group without a fully established intestinal flora, may have unknown adverse effects. There 
are however, to our knowledge, no studies investigating possible short or long term adverse 
health effects of F19 in processed cereal-based baby food given to children 13 months 
onwards. 
The documentation and information provided by the notifier regarding the genetic stability of 
F19 in the two products during processing and storage, is considered insufficient and does not 
allow any conclusions to be drawn.  
Moreover, the documentation obtained is not conclusive regarding the antibiotic resistance 
pattern of the bacterial strain used in the products in question, as the information on different 
antibiotics is partly inconsistent. The information about specific localization (chromosomal, 
plasmid) of the resistance genes is not sufficient.  
Studies demonstrate that F19, as well as other bacterial strains considered probiotic, is able to 
“crosstalk” with enterocytes in mice and that the result of the “crosstalk” depends upon the 
microbiota present. Whether F19 has a similar “crosstalk-profile” in humans is unknown. 
However, as the strain is originally of human origin, it seems reasonable to assume that such 
“crosstalk” may occur. Thus, before giving F19 daily for months and years, it seems 
reasonable to ask for additional molecular and physiological studies to unravel the functional 
impact of possible changes in genetic expression in children.  
Lactobacillus infections do occasionally occur, mainly as bacteremia, endocarditis and 
localized infections (e.g. abscesses, peritonitis, and meningitis) in patients with severe 
underlying diseases. Most of them are elderly, but children are not excluded. The species 
most often isolated are L. casei and L. rhamnosus, followed by L. paracasei.  
The increasing use of immunosuppressive therapy and broad spectrum antibiotics which are 
ineffective against Lactobacillus, might increase the importance of these bacteria as possible 
pathogens. In order to be able to draw any conclusions regarding beneficial effects of F19, 
there is a need for randomized placebo-controlled studies in larger populations and in the 
relevant age group.  
According to EFSA, Lactobacillus paracasei ssp. paracasei F19 is sufficiently characterized. 
The documentation provided is, however, not sufficient to claim positive health effects and 
thus F19 is not proven to be probiotic.  
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There are no published dose-response studies of F19 in children, neither regarding survival of 
F19 in the gastrointestinal tract, nor possible negative health effects. Thus the potential for 
negative health effects as e.g. spreading of antimicrobial resistance or unfavourable impact on 
the genetic expression in children related to the frequency and/or dose of a monoculture of 
F19 cannot be assessed.  
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Norsk sammendrag 
Vitenskapskomiteen for mattrygghet (VKM) har på oppdrag fra Mattilsynet utarbeidet en 
nytte- og risikovurdering av Lactobacillus paracasei ssp. paracasei F19 (F19) tilsatt i 
barnegrøt til barn i alderen 1-3 år. For å besvare oppdraget nedsatte VKM en ad hoc-gruppe. 
Vurderingen er basert på gjennomgang av litteratur tilsendt fra virksomheten og MEDLINE 
litteratursøk.  
Bakgrunnen for oppdraget er en innmelding av to barnegrøter tilsatt F19 i Norge. 
Daglig tilgang på en monokultur av en spesiell bakteriestamme i store mengder til en 
aldersgruppe uten fullt etablert tarmflora kan gi uønskede effekter. Så langt er det ikke gjort 
studier som undersøker kort – eller langtidsbivirkninger av F19 brukt i barnegrøt til barn eldre 
enn 13 måneder. 
Dokumentasjonen oversendt fra søker angående genetisk stabilitet av F19 i de to produktene 
anses som utilstrekkelig slik at ingen konklusjoner kan trekkes.  
Videre ansees ikke dokumentasjonen vedrørende antibiotika resistensmønsteret for 
bakteriestammen som er brukt i produktet klar siden informasjonen for enkelte antibiotika 
varierer. Informasjon om lokalisering av resistensgener (kromosomalt, plasmid) er heller ikke 
tilstrekkelig.  
Studier viser at F19 og andre probiotiske stammer kan ”kommunisere” med enterocyter i mus 
og resultatet av ”samtalen” avhenger av tilstedeværelsen av mikrobiota. Om F19 har samme 
”samtaleprofil” hos mennesker er uvisst. Stammen er imidlertid av human opprinnelse, så slik 
”kommunikasjon” kan være sannsynlig. Før F19 tilføres daglig i måneder og år, er det rimelig 
å be om molekylære og fysiologiske studier, for å avsløre den funksjonelle virkningen av 
mulige endringer i barns genetisk uttrykk. Lactobacillus-infeksjoner forekommer en sjelden 
gang som bacteriemi, endokarditt og lokale infeksjoner (for eksempel absesser, peritonitt, 
meningitt) hos pasienter med alvorlige underliggende sykdommer. Mange av dem er eldre, 
men barn er ikke unntatt. Stammene som oftest blir isolert er L. casei og L. rhamnosus, 
deretter L. paracasei. 
Den økende bruken av immunosuppressiv behandling og bredspektret antibiotikum som ikke 
virker mot Lactobacillus kan øke betydningen av disse bakteriene som mulig 
sykdomsfremkallende. For å kunne trekke konklusjoner om nytte-effekter av F19 er det 
nødvendig å gjøre randomiserte placebokontrollerte studier i større populasjoner og i 
relevante aldersgrupper. 
Ifølge EFSA er Lactobacillus paracasei ssp. paracasei F19 tilstrekkelig karakterisert. 
Dokumentasjonen som finnes er allikevel ikke god nok til å hevde positive helseeffekter, og 
det er derfor ikke bevist at F19 har probiotisk effekt. 
Det finnes ingen publiserte dose-respons studier av F19 hos barn, verken når det gjelder 
overlevelse av F19 i mage-tarmkanalen eller mulige negative helseeffekter. Således kan 
potensialet for negative helseeffekter, som for eksempel spredning av antimikrobiell resistens 
eller uønsket påvirkning på det genetiske uttrykk hos barn relatert til frekvens og/eller dose av 
monokultur av F19, ikke vurderes.  
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Background 
In 2008 and 2009, the Norwegian Food Safety Authority (Mattilsynet) received a notification 
regarding two types of processed cereal-based baby foods containing the probiotic 
microorganism Lactobacillus paracasei ssp. paracasei F19.     
The addition of probiotics of different bacterial species and strains to regular foods, including 
infant formulas and baby foods, is increasing. 
Foods with added probiotics, and in particular milk products for children, are being 
increasingly promoted by the food industry. It has been claimed that these microorganism can 
play an important role in immunological, digestive and respiratory functions and could have a 
significant effect in alleviating infectious disease in children as well as adults. 
The notifier has provided documentation on the origin of the bacterial strain Lactobacillus 
paracasei ssp. paracasei F19, and the manufacturing process. Documentation on microbial 
and chemical safety was included in the notification.  
In May 2009, the Norwegian Food Safety Authority requested the Norwegian Scientific 
Committee for Food Safety (VKM) to make an assessment of the benefits and risks of the 
addition of Lactobacillus paracasei ssp. paracasei F19 in two processed cereal-based baby 
foods, and an ad hoc-group of experts was appointed of the Panel on biological hazards and 
the Panel on nutrition, dietetic products, novel food and allergy with the mandate to draft this 
assessment.  
VKM has previously published four assessments of the use of probiotics; Assessment of 
benefits and risk of probiotics in processed cereal-based baby foods - Bifidobacterium lactis 
Bb12 (VKM, 2010), Benefit and risk assessment of the use of probiotics for patients in 
hospitals (VKM, 2009), Risk assessment on use of Lactobacillus rhamnosus (LGG) as an 
ingredient in infant formula and baby foods II (VKM, 2007) and Risk assessment on use of 
Lactobacillus rhamnosus (LGG) as an ingredient in infant formula and baby foods (VKM, 
2005). 
Furthermore, the European Food Safety Authority (EFSA) has assessed and dismissed several 
health claims and nutrition claims related to probiotics.  
All these reports and opinions have been valuable background documents in this assessment. 
 
Terms of reference 
Translated from the Norwegian terms of reference1: 
1. What benefit can children (1 to 3 years) have from consuming processed cereal-based 
food containing Lactobacillus paracasei ssp. paracasei F19?  
2. What impact can the addition of Lactobacillus paracasei ssp. paracasei F19 to 
processed cereal-based food for children (1 to 3 years) have on the development of 
allergy?  
                                                 
 
1
 Norwegian terms of reference are listed in Appendix I 
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3. Are there any contraindications regarding the consumption of processed cereal-based 
food containing Lactobacillus paracasei ssp. paracasei F19 for children (1 to 3 
years)?  
4. Is there any risk that the consumption of processed cereal-based food containing 
Lactobacillus paracasei ssp. paracasei F19 can lead to a spreading of antimicrobial 
resistance to other members of the gut microbiota?  
5. What possible negative health effects are correlated to the daily consumption of 
processed cereal-based food containing Lactobacillus paracasei ssp. paracasei F19? 
Furthermore, will an increased consumption (amount and frequency) result in 
pronounced effects?  
6. Do the products contain ingredients that can have prebiotic effect?  
 
 
1 Information provided by the notifier 
Two processed cereal-based products (oat cereal and multi-grain cereal) with F19 have been 
notified. 
The literature provided by the notifier regarding the origin of Lactobacillus paracasei ssp. 
paracasei F19 (F19) is not consistent, see section 3.1. 
The bacterial culture is supplied by Christian Hansen (Denmark). The strain has been 
deposited at Belgian Coordinated Collections of Microorganisms - BCCM, LMG collection, 
with the accession No. LMG P-17806. 
The number of viable cells of the culture in a portion of the cereal powder has been given as 
108 cfu according to information from the notifier. 
 
1.1 Food/constituent as stated by notifier  
The oat cereal contains 34% full corn cereal of which 22.7% is oat flour. The multigrain 
cereal contains 40% full corn cereal, of which 10.5% is oat flour and 9.5% is sifted wheat 
flour. Both products contain dairy based powders and fruit additions. Vitamins and minerals 
are added. The product contains the probiotic bacterium F19. 
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Table 1: Nutritional content of the two notified cereal products  
 
Nutritional 
content /100g 
Multi-grain 
cereal with 
apple & pear + 
probiotics 
Oat-cereal with 
probiotics 
Energy kJ 1800 1850 
Protein 15 % 15 % 
Carbohydrate 55 % 54 % 
    -  of which, 
sugars 23 % 29 % 
Fat 17 % 18 % 
    - saturated 5 % 5.50 % 
    - mono-
unsaturated 7 % 7.50 % 
    - 
polyunsaturated 5 % 4.50 % 
 
The cereal powder is to be prepared by stirring the cereal mixture into hot water 
(approximately 50°C). The consumer is advised to avoid too hot water as the “The bacteria 
culture does not tolerate heating above 60°C”. The Norwegian labelling text is given in 
Appendix II. 
 
1.2 Wording of the health claims as proposed by the notifier2 
Foods containing probiotics are commonly marketed with different nutritional and health 
claims. Health claims related to probiotics are currently and continuously assessed by EFSA. 
So far none of the health claims related to probiotics have been accepted as sufficiently 
documented by EFSA, (see list of EFSA opinions in chapter 2 Data sources). The claimed 
health effects of the two products in question are similar to those assessed by EFSA for other 
probiotic bacteria.  
The following labelling claims are suggested by the notifier for multi-grain cereal and oat 
cereal:  
                                                 
 
2
 Free translation of Norwegian labelling text and text from notifiers website. Norwegian labelling and text from 
notifiers website is given in Appendix II 
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• “Contains probiotic lactic acid bacteria that have scientifically documented 
properties.”  
• “Probiotic lactic acid bacteria are naturally found in our intestines and an extra 
addition of these can contribute to maintain a healthier and more robust gut flora. The 
digestive tract is the body’s most important immune organ (lit. system).” 
• “Probiotics keep the gut in balance!” 
•  “The cereal is appropriate for children from 1 ½ years, and with the addition of 
probiotic bacteria it is well-suited for children right up to school age” (on the oat 
cereal only). 
Additional information about probiotics in the notified processed cereal-based food is given 
on the notifiers website: 
• “Will improve the immune system.” 
• “Probiotics have been shown to have a healthy effect on children and adults.” 
• “A complex intestinal flora provides protection against colonisation by harmful 
bacteria, by creating competition for nourishment and space. It is these abilities of 
intestinal bacteria to stimulate the immune system and to compete with harmful 
bacteria that have led to the development of probiotics.” 
• “Probiotic lactic acid bacteria are harmless bacteria that may be added to food and 
drink. Research has shown that some probiotics have a good effect on certain 
infections and inflammatory conditions in children.” 
• “Probiotic bacteria survive the gastrointestinal tract and "settle" in the gut for a while 
and can help in maintaining a healthier and more resistant flora. However, it is 
important that there is a steady supply of further bacteria, as they will disappear if 
more are not added.” 
 
1.3 Specific conditions of use as proposed by the notifier 
One portion per day is recommended on the packet for children over 1 year, for the oatmeal 
porridge above 1.5 years. One portion consists of 1 dl water and 35g (5 dessert spoonfuls) of 
cereal powder. The number of viable cells of the culture in a portion (35g) of the cereal 
powder has been given as 108 cfu. 
The shelf life of the product is 1 month after opening, provided it is kept dry and at or below 
room temperature.  
 
2 Data sources 
Articles and reports provided by the notifier (see Appendix III) have been assessed when the 
products in question and the appropriate probiotic strain have been studied, i.e. only articles 
on Lactobacillus paracasei ssp. paracasei F19 has been included. Human studies have been 
assessed when relevant for children 12 months to 3 years. 
Additional literature search in MEDLINE and EMBASE using the map terms Lactobacillus 
OR probiotics and F19 OR F-19 has been conducted. From the MEDLINE and EMBASE 
search all relevant human studies investigating positive or negative health effects from F19 in 
English, Norwegian, Danish and Swedish were assessed. Articles and reports investigating 
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F19 in cereals and preferably in the relevant age group (1 to 3 years) have been considered 
most relevant. Few studies have investigated F19 in humans, and some relevant animal 
studies have therefore also been included. 
Only articles published in peer-reviewed journal have been considered. Thus studies that are 
only published in the supplement Microb Ecol Health Dis 2002 Suppl 3, which is not peer-
reviewed, should not be taken into consideration. However, since there are very few studies 
involving F19, children and safety, some of the studies in the above mentioned supplement 
are nevertheless commented upon. 
Background papers used in this assessment are previous opinions on probiotics from EFSA 
related to F19, QPS and health claims.  
• Opinion on the substantiation of health claims related to Lactobacillus casei F19 (LMG P-
17806) and bowel motor function. (EFSA, 2009b)  
• Opinion on the maintenance of the list of QPS (Qualified Presumption of Safety) 
microorganisms intentionally added to food or feed. (EFSA, 2009a)  
• Opinion on the substantiation of health claims related to non-characterised 
microorganisms. (EFSA, 2009c) 
• Draft guidance on the scientific requirements for health claims related to gut and immune 
function. (EFSA, 2010) 
Other assessments and opinions from VKM and EFSA that have been valuable background 
papers in this assessment are listed in Appendix IV. 
 
3 Hazard identification and characterisation 
EFSA has recently established a draft for guidance on the scientific requirements for health 
claims related to gut and immune function , and decided to use FAOs criteria for 
characterisation of probiotics (EFSA, 2010). In the EFSA guidelines it is mentioned:  
“ microorganisms (e.g. bacteria, yeast), should be sufficiently characterised (genetic typing) at 
strain level by internationally accepted molecular methods and strains should be named 
according to the International Code of Nomenclature. Strains should be deposited in an 
internationally recognized culture collection (with access number) for control purposes. For 
manufacturing processes, information should be provided to show consistency in the final 
product for those characteristics considered pertinent to the claimed effect. The 
characterisation should also be sufficient to allow control authorities to verify that the 
food/constituent which bears a claim is the same one that was the subject of a community 
authorisation.” 
According to the FAO “Guidelines for the evaluation of probiotics in food”, strains should be 
identified at species level by DNA-DNA hybridisation or 16S rRNA sequence analysis. 
Strains should be characterised at strain level by DNA macro-restriction followed by Pulsed-
Field Gel Electrophoresis (PFGE), Random Amplification of Polymorphic DNA (RAPD), 
amplified rDNA restriction analysis (ARDRA) or other internationally accepted genetic 
typing molecular methods (FAO, 2002).  
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3.1 Specific properties of F19 
The FAO guidelines suggest the following definition of probiotics: “Live microorganisms 
which when administered in adequate amounts confer a health benefit on the host”.  
 
3.1.1 Origin of the F19 strain 
Information concerning the origin of the strain is divergent in different publications. The 
following origins have been published: 
• Colonic mucosa in healthy subjects (Kruszewska et al., 2002). 
• Deep colonic mucus layer in non-gastrointestinal diseased patients post mortem 
(Ljungh et al., 2002). 
• Small intestine in a human subject (Crittenden et al., 2002). 
 
3.1.2 Determination of the presence of plasmids, insertion sequence element, 
transposons, integrons and other transposable elements 
According to Morelli and Campominosi, the F19 strain contains three plasmids of 2.2, 6.5 and 
9.0 kb (Morelli and Campominosi, 2002). Additional information on the plasmids is given in 
the patent application where it is stated “and containing three plasmids having a size of 2.2, 
4.36 and 9.1 kb, respectively” (http://www.freepatentsonline.com/6599504.html). 
According to the notifier, the genome of the strain has been sequenced, but the sequence data 
has not been made available. As we do not have access to the sequence data we have no 
information regarding the presence of insertion sequence elements (IS-elements), transposons, 
integrons or other mobile genetic elements in the F19 strain. 
 
3.1.3 Antimicrobial resistance properties of F19 
Information concerning the antimicrobial resistance properties of F19 is divergent in 2 
different publications (Morelli and Campominosi, 2002).  Patent application 
http://www.freepatentsonline.com/6599504.html; Arla). 
According to Morelli and Campominosi, F19 exhibits resistance to vancomycin, gentamicin, 
colistin, kanamycin, streptomycin, and polymixin B (Morelli and Campominosi, 2002).  
According to Arla patent application (http://www.freepatentsonline.com/6599504.html), F19 
exhibits resistance to, gentamycin, colistin, kanamycin, streptomycin, trimethoprim and 
cefotaxime, azteronam, ceftaxidime, cefoxitin, polymixin B and vancomycin. In the same 
patent application F19 is described to be susceptible to eleven antibiotics including 
streptomycin, penicillin G, ampicillin, bacitracin, clindamycin, chloramphenicol, 
erythromycin, rifampicin, tetracycline and trimethoprim. 
 
3.1.4 Pathogenic criteria 
Some probiotic strains may be able to translocate. However, a search in PubMed revealed no 
publication in which this question was addressed for F19, indicating that it might not have 
been investigated. 
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The possibility that probiotics may be able to aggregate platelets in vivo was recently 
commented upon (Halvorsen et al., 2009). Studies have demonstrated that certain 
Lactobacillus strains (e.g. belonging to the species L. rhamnosus and L. paracasei ssp. 
paracasei) isolated from patients with endocarditis possess pathogenic traits such as platelet 
aggregation, binding to fibronection and collagen, and production of enzymes enabling the 
breakdown of human glycoprotein and the synthesis of human fibrin clots (Harty et al., 1994). 
To the best of our knowledge, there are no reports of investigations into whether F19 possess 
such pathogenic traits. 
 
3.1.5 Potential pathogenicity 
Lactobacilli are ubiquitous commensals of the normal human flora. Although usually 
considered as extremely rare causes of infections in humans, they have occasionally also been 
involved in serious infections. They have been associated with septicaemia and endocarditis 
and some cases of severe localised infections like meningitis and abscesses in lung or liver 
(Husni et al., 1997).  
The species involved were mainly L. rhamnosus and L. casei, but also include some cases 
with L. paracasei. The great majority of the patients had severe underlying diseases and the 
role of Lactobacillus as a potential pathogen was linked to immunosuppression, use of broad 
spectrum antibiotics and surgery. The patients were mainly elderly, but some isolations were 
from children (Cannon et al., 2005). 
An evaluation of Lactobacillus-induced bacteraemia in Stockholm during the period 1998-
2004 identified 71 cases (< 1% of the total number of bacteraemia cases) (Sullivan and Nord, 
2006). The majority of cases were caused by L. rhamnosus and L. paracasei ssp. paracasei, 
but none of the strains were found to be identical to probiotic strains. 
However, a retrospective study from Finland identified 89 cases of Lactobacillus bacteremia 
between 1990 and 2000. 47 of the strains were identified to species level, 25 of whom were 
identified as L. rhamnosus (11 of these as L. rhamnosus GG - coinciding with a general 
increase in consumption of probiotics) (Salminen et al., 2004). 
One article presents two cases of Lactobacillus rhamnosus GG sepsis directly associated with 
the use of probiotic therapy (Land et al., 2005). Both cases were children (6 weeks and 6 
years old respectively) and both had severe underlying diseases.  
Lactobacilli do not readily grow on bacteriological media typically used for clinical 
specimens, and may therefore be overlooked by bacteriological examinations. On the other 
hand, as ubiquitous commensals they may also contaminate bacteriological specimens, and 
the significance when isolated from infectious sites may therefore also be easily 
overestimated. The clinical significance of such strains isolated from normally sterile sites is 
therefore a subject of ongoing debate (Cannon et al., 2005). 
 
3.1.6 Summary specific properties of F19 
In summary, F19 is a well-characterised strain of L. paracasei ssp. paracasei.  It contains 3 
plasmids, but there is no information about the presence of other mobile genetic elements. 
Like many lactobacilli, the strain is resistant to several antimicrobials of clinical importance, 
in particular vancomycin. No information is available about possible pathogenic properties of 
this strain. Lactobacilli are occasionally isolated from clinical specimens, but the strain F19 
has not been specifically implicated. 
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3.2 Adaptive properties of F19 in the gastrointestinal tract and effect on 
epithelial cells 
 
3.2.1 Resistance to gastric acidity 
Following ingestion and swallowing, bacteria enter the extremely acidic environment of the 
stomach which is normally about pH 2-3, but may be as low as 1. In vitro tests are mostly 
based on exposing the bacteria culture to a pH between 2 and 3 for varying lengths of time, 
and the methodology used varies. Usually acidified MRS (de Man, Rogosa and Sharpe) broth 
is used, but also acidified MRS agar, phosphate buffered saline or HCl solutions have been 
used. The exposure time varies from 1 to 10 hour but considering the short time that food is in 
the stomach three hours is probably the most relevant time.  
There are no published dose-response studies of F19 in children, and no general opinion on 
doses necessary to survive the acid environment in the stomach.  
According to the Arla patent application (http://www.freepatentsonline.com/6599504.html), 
the strain is characterised by being tolerant in vitro against HCl and gastric juice. 
In vitro studies by Ljungh et al. showed that F19 tolerated pH 2.5 for one hour (Ljungh et al., 
2002). Dunne et al., 2001 also showed that F19 tolerated pH 2.5 for one hour, but were 
severely reduced after 5 minutes at pH 1.2, and the strain could not be isolated after 30 min 
(Dunne et al., 2001). The clinical relevance of these findings is unclear. 
 
3.2.2 Bile salt resistance 
Bacteria that survive the acid conditions in the stomach enter the duodenum in a stressed state 
and then encounter a more neutral pH and bile salts.  
The physiological concentration of bile salts is around 0.3%. In vitro testing for bile tolerance 
usually employs an appropriate broth (usually MRS broth) to which bile salts have been 
added. Concentrations used in various studies range from 0.3 to 7.5% and survival has been 
assessed after periods ranging from one to 48 hours.  
F19 survived 20% bile for two hours according to Ljungh et al. (Ljungh et al., 2002) and 
according to (http://www.probioticblends.com/docs/probiotic-l-paracasei-f19.pdf) this strain 
was able to actually grow in bile salt concentrations of 0.3 and 0.5%, and numbers remained 
stable at an exposure to 5% for 8 hours. Dunne et al. reported that several strains tested, 
including F19, could grow in “physiologically relevant concentrations of human bile” (Dunne 
et al., 2001).  
According to the Arla patent application (http://www.freepatentsonline.com/6599504.html), 
the strain is characterised by being tolerant in vitro against HCl and gastric juice and by 
tolerating bile salts without deconjugating them and by having the ability to assimilate 
cholesterol. 
During the first years of life (i.e. up to 3 years), the secreted bile salts change in their 
composition and conjugating properties.  We are not aware of any in vitro study of F19 using 
types of bile salts relevant for small children or of any study showing assimilation of 
cholesterol by F19 in vivo. 
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3.2.3 Adherence to mucus and/or human epithelial cells and cell lines 
The ability to adhere to intestinal surfaces is thought to be important for the efficacy of 
probiotic strains. The mucus covering the epithelial cells is the initial surface that ingested 
microorganisms confront in the human gut, and is considered an important site for bacterial 
adhesion. It is believed that mucus has receptors mimicking the epithelial cells, to which the 
bacteria adhere. Mucus is, however, continually subjected to degradation and washed away 
with the luminal contents (including their content of microorganisms). In this way bacteria 
may consequently be prevented from reaching the enterocytes.  
Assessment of bacterial adhesion in vivo is difficult, and in vitro models are therefore 
commonly applied for this purpose.   
The ability of different probiotic strains, including F19 to adhere to mucus isolated from 
infants (newborn, 2 and 6 months old) and adults was examined in vitro. F19 was shown to 
adhere rather weakly and significantly weaker to mucus from infants than from adults (appr. 
6% versus 9.7%) (Kirjavainen et al., 1998).   
Another in vitro study was designed to assess whether the adhesion to mucus was affected by 
an ongoing rotavirus infection (Juntunen et al., 2001). The rotavirus infection did not decrease 
the production of fecal mucin and the adherence of F19 was not affected. The overall results 
were similarly to those found by Kirjavainen. 
The fact that probiotic bacteria in general have a transient pattern of presence in feces, may 
indicate that adherence may not be of critical importance for their efficacy. The survival and 
ecology of F19 in human subjects have been investigated in a multicentre European research 
project, PROBDEMO, and it was shown that in doses between 108-1010 cfu, F19 only 
transiently colonised the colonic lumen and the mucosa (PROBDEMO, 2002). In some young 
children the colonisation lasted for up to 2 weeks after cessation of intake and 2 elderly 
subjects were still colonised after 8 weeks.  
In another study F19 remained in 8% and 20% in children and elderly persons respectively for 
several weeks (Sullivan et al., 2002). In these cases F19 seems to have been established as 
part of the normal microbiota.  
We are unaware of any in vivo studies concerning the specific ability of F19 to adhere directly 
to human enterocytes or mucus. 
 
3.2.4 Physiological aspects 
Commensals, including probiotics have been found to “cross-talk” with enterocytes. The 
results from comparative studies in conventional and germfree mice demonstrated that F19 
influenced the expression of “a number of genes involved in essential physiological functions 
such as immune response, regulation of energy homeostasis and host defense” (Nerstedt et al., 
2007).  However, this response was different in the germfree vs. conventional mice. The 
authors underlined that “any impact of Lactobacillus feeding is likely to be affected by factors 
such as age, sex, health status, already existing gut microflora etc”. 
 
3.2.5 Summary adaptive properties of F19 in the gastrointestinal tract and effect on 
epithelial cells 
According to the Arla patent application (http://www.freepatentsonline.com/6599504.html), 
the strain is characterised by being tolerant in vitro against HCl and gastric juice and by 
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tolerating bile salts without deconjugating them and by having the ability to assimilate 
cholesterol. However, during the first years of life (i.e. up to 3 years), the secreted bile salts 
change in their composition and conjugating properties.  We are not aware of any in vitro 
study of F19 using types of bile salts relevant for small children. 
The ability to adhere to intestinal surfaces is thought to be important for the efficacy of 
probiotic strains. The survival and ecology of F19 in human subjects have been investigated 
in a multicentre European research project, PROBDEMO, and it was shown that F19 only 
transiently colonised the colonic lumen and the mucosa. Another in vitro-study showed that 
F19 adhered rather weakly to mucus and significantly weaker to mucus from infants than 
from adults (Kirjavainen et al., 1998).   
Commensals, including probiotics have been found to “cross-talk” with enterocytes. In animal 
studies, F19 was shown to influence the expression of “a number of genes involved in 
essential physiological functions such as immune response, regulation of energy homeostasis 
and host defense”. Any impact of Lactobacillus feeding is likely to be “affected by factors 
such as age, sex, health status, already existing gut microflora etc” (Nerstedt et al., 2007). 
 
3.3 Health effects of intake of F19 
Positive and adverse health effects of probiotics are considered to be mainly species and strain 
specific and therefore only studies investigating the specific strain are relevant in assessing 
benefits and risks from the products in question. Moreover, the food matrix may be of 
importance when assessing safety and efficacy, although this is probably not as significant as 
strain specificity.  
Articles and reports investigating F19, preferably in the relevant age group (12 months to 3 
years) have been considered sufficiently relevant to be included in this report. 
West et al. studied F19 in cereals for children 4 to 13 months (West et al., 2008), which make 
these studies relevant for the product in question although the present product is intended for 
use in children 12 months and older. This is the only report available studying the processed 
cereal-based food containing F19, but the product was only given to children in the relevant 
age group. 
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Table 2:  Studies with F19 given to children below 3 years of age. 
 
Author Journal Number of 
children 
Age 
 
Sullivan, et al. 
Micr J Health 
and Dis, 2002 
Suppl 3 
77 (16 drop outs) 
30 active 31 
placebo 
12 months 
(SD1.4)  
13 months (SD2)  
 
Crittenden et al. 
 
Micr J Health 
and Dis, 2002 
Suppl 3 
 
61 12 – 18 months 
West, Christina Umeå University 
medical 
dissertations, 
2008 
179 (8 drop outs) 
89 active 90 
placebo 
4-13 months 
Kirjavainen et al. Microbiology 
letters, 2006 
56 0 – 6 months 
Juntunen, et al. Clinical & Diagnostic  
Laboratory 
Immunology 
2001 
30  
20 (rotavirus) + 
10 (control) 
 
6 – 42 months 
 
3.3.1 Safety studies 
Grzeskowiak et al., suggest that different sources of the same probiotic may have 
significantly altered strain properties and underlined the importance of control of the 
manufacturing process and the food matrix (Grzeskowiak et al., 2011). The notifier has not 
supplied any safety studies of F19 in processed cereal-based products. 
The EFTA PROSAFE workshop (Product Safety Enforcement Forum of Europe) discussed 
recommendations on taxonomy, antibiotic resistance, in vitro assessment of safety and 
recommendations for in vivo assessment of safety of probiotics used for human consumption 
(PROSAFE, 2008). Consensus was reached for approving the necessity of bacterial 
colonisation studies in humans in a randomised placebo controlled design. 
The PROBDEMO project was designed to also unravel safety issues, and the results from 
project were published in supplement 3 Microb Ecol Health Dis. 2002. No adverse effects 
were noted after feeding young children with freeze dried F19 in capsules (Sullivan and Nord, 
2006). In the same project Sullivan et al. investigated the impact on the intestinal microflora 
by feeding F19 to small children (12-18 months).  
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As part of a multicentre European project F19 was included in four pilot feeding studies. The 
target groups in these studies ranged from infants to elderly and included both healthy 
subjects and individuals with mild health disorder (milk hypersensitivity and H. pylori 
infection). No adverse effects attributable to the administration of F19 were observed in any 
of the pilot studies (Crittenden et al., 2002). 
There are no studies designed to unravel the long-term safety aspects of feeding F19 to young 
children on a daily basis. However, the studies by Christina West reported in her doctoral 
thesis describe children fed processed cereal-based baby food containing F19 from weaning at 
4 months until 13 months of age (West et al., 2008). The supplemented processed cereal-
based baby food was well tolerated.  
F19 has been given to mice, both ordinary and mice treated with cyclophosphamid (a 
substance making the mice sensitive to infections). In spite of this treatment, the mice showed 
no side effects attributable to the intake of F19 (Wang et al., 1998). 
Nerstedt et al. showed that the genes in the intestinal cells were switched on/off in laboratory 
mice exposed to F19 (Nerstedt et al., 2007). The mere fact that F19 originate from human 
intestinal microbiota makes it reasonable to assume that similar microbe/cell interactions may 
take place in children. However, we are not aware of studies, in vitro or in vivo, in which such 
interactions have been studied on human cells. 
 
3.3.1.1 Summary safety studies 
Few studies are designed to unravel safety issues concerning feeding F19, and there are no 
studies on long-time safety. Furthermore, the only studies on short-time safety have been  
published in a non peer-reviewed supplement to an otherwise peer-reviewed journal 
(Supplement 3 Microb Ecol Health Dis. 2002). Studies focusing on safety do not demonstrate 
any short term adverse effects.  
 
3.3.2 Studies on beneficial effects 
3.3.2.1 Effect on development of allergies and atopic eczema 
A beneficial effect with respect to the development of atopic eczema following the feeding of 
F19 to infants from weaning at 4 months to 13 months of age was demonstrated by West et al. 
(West et al., 2008). Healthy infants (n=179) delivered at term were included in the study, 8 
drop outs due to removal of consent. Eighty-four infants were given F19 in processed cereal-
based baby food from 4 months of age and 87 infants constituted the placebo group. The 
incidence of eczema was 11% and 22% in the treatment and placebo group respectively 
(p=0.049). However, a beneficial effect on development of allergies and atopic eczema from 
processed cereal-based baby food fortified with F19 from 12 months onwards has not been 
investigated. Furthermore, the demonstrated effect was only marginally significant and the  
clinical significance of these results is therefore questionable. 
There was no indication that allergic sensitisation was reduced in the probiotic group. 
 
3.3.2.2 Effect on infections 
West et al. could not demonstrate any difference in the number of days of infection between 
the children fed processed cereal-based baby food fortified with F19 and the placebo group 
(West et al., 2008). However, the probiotic group did have marginally significantly fewer 
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days with the administration of antibiotics compared with the placebo group (p=0.044). This 
finding may be questioned since most infections in young children are viral and thus not to be 
susceptible to antibiotics.  
 
3.3.2.3 Summary of studies on beneficial effects 
F19 has, in one study, been shown to result in less atopic eczema when given to infants from 
weaning at 4 months until 13 months of age (West et al., 2008). Based on a marginal 
statistical significance in one study no conclusions should be drawn. The group of children 
given the fortified processed cereal-based baby food was less prone to be given antibiotics 
than the placebo group, but no significant positive effect on infections was demonstrated.  
There is no documentation for effect on general maintenance of a healthier and more robust 
gut flora, nor documentation of reduced allergic sensitisation. 
 
4 Exposure assessment 
Intake of processed cereal-based foods in children above 12 months in Norway (Spedkost - 
12 months and Småkost - 2 years) 
The notifier has informed that a portion of cereal contains 108 cfu of viable cells of F19. 
According to the wording on the package, one portion of this cereal per day is recommended. 
One portion of the prepared cereal weighs about 135 g. 
The labelling contains no warning about serving more than one portion per day.  
Data on intake of processed cereal-based food in 1 year olds and 2 year olds are available in 
Spedkost and Småkost (Helsedirektoratet, 2009). At the age of 12 months 87% of the infants 
were given porridge on a daily or weekly basis. Most infants (82%) were given commercially 
manufactured processed cereal-based baby food. Among these, average intake (ready to eat) 
was 265 g/day. An intake of 265g/day would therefore be equivalent to approximately 2 x 108 
cfu in the notified products. 
As described above more than 80% of 12 month old children were fed processed cereal-based 
baby food and the daily intake was relatively high. Thus a processed cereal-based baby food 
containing probiotic bacteria could provide a daily intake containing a high bacterial load, and 
thus disturbing the evolution of a normal balanced bacterial diversity. There are no published 
dose-response studies of F19 in children. 
 
5 Risk and benefit characterisation 
Information concerning the origin of the strain is divergent in different publications, as 
mentioned in section 3.1.1. The source of the strain had been given as the colonic mucosa in 
healthy subjects (Kruszewska et al., 2002), the deep colonic mucus layer in non-
gastrointestinal diseased patients post mortem (Ljungh et al., 2002) or from the small intestine 
in a human subject. (Crittenden et al., 2002). VKM finds this divergence disconcerting since it 
indicates a lack of dependable traceability for the strain. Also it is not possible to isolate one 
strain from several subjects. 
The information from the notifier regarding the genetic stability of F19 in the two products 
during processing and storage is considered as insufficient and does not allow any 
conclusions to be drawn. 
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5.1 Safety 
The four studies included in the doctoral thesis of Christina West et al. are the only studies in 
humans pertaining to benefit and safety of F19 in small children (West et al., 2008). Two of 
these articles are to date published in peer reviewed journals. The investigations were not 
designed to unravel safety issues, but no short term adverse effects were observed. Long term 
adverse effects were not studied as the intervention ended at 13 months of age. There are no 
studies investigating the effect of F19 on infections in the relevant age group. 
A daily supply of a monoculture of a particular bacterial strain in large quantities to an age 
group without a fully established intestinal flora may have unknown adverse effects.  There is 
however, to our knowledge, no studies investigating possible short or long term adverse 
health effects of F19 in processed cereal-based baby food given to children 13 months 
onwards. 
In the PROBDEMO project it was concluded that in order to be able to draw any conclusions 
regarding the safety of F19, there is a need for randomised placebo-controlled studies in 
larger populations (PROBDEMO, 2002). Differences in establishment of a normal gut flora 
should be investigated. Long term follow up including clinical parameters is missing. 
 
5.2 Possible association between antimicrobial resistance phenotype and 
resistance genes 
Information provided by the notifier regarding possible association between antimicrobial 
resistance phenotype and resistance genes is insufficient and partly inconsistent. The 
documentation obtained is not conclusive regarding the antibiotic resistance pattern of the 
strain used in the products in question , as the information on different antibiotics also are 
partly inconsistent. The information about specific localisation (chromosomal, plasmid) of the 
resistance genes is not sufficient. Furthermore, there is lack of data regarding possible 
association between the resistance genes with IS-elements, transposons, integrons, and other 
mobile genetic elements in F19.  
Morelli et al. concluded that all plasmid-cured derivates (cured for 6.5 and 9.0 kb plamids) of 
F19 exhibited the same resistance profile as non plasmid-cured F19 (Morelli and 
Campominosi, 2002). The authors concluded that this is an indication that the resistance 
phenotype is not encoded by plasmids with molecular weights 6.5 and 9.0 kb. This conclusion 
may be correct, although it does not exclude that genes encoding resistance to these 
antimicrobial agents are located on other transposable genetic elements (including the 
smallest plasmid). This has not been investigated, either by Morelli et al. (Morelli and 
Campominosi, 2002), or by others. Molecular methods such as Polymerase Chain Reaction 
(PCR) may confirm the presence of resistance genes in F19. Should this be the case, the 
localisation of the gene(s) on plasmid(s) or chromosome should be confirmed by 
hybridisation study.  
The notifier has been given the opportunity to clarify this inconsistency and to supply 
additional documentation on several occasions. 
According to the guidelines for probiotics in food (FAO, 2002), it is recommended that use of 
probiotic bacteria should be restricted to those strains that do not harbour transmissible drug 
resistance genes encoding resistance to clinically used drugs.  
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5.3 Interference with host genes 
In the first 2-3 years of a child’s life, a considerable number of bacterial species (possibly 
more than 2000) become established in the gastrointestinal tract, and each of them may 
“crosstalk” with the enterocytes, thereby shaping the phenotypic expression of the host. The 
data presented by Nerstedt demonstrate that F19 is able to “crosstalk” with enterocytes in 
mice and that the result of the “crosstalk” depends upon the microbiota present (Nerstedt et 
al., 2007). Whether F19 has a similar “crosstalk-profile” in humans is unknown. However, as 
the strain is originally of human origin, it seems reasonable to assume that such “crosstalk” 
may take place. Thus, before giving F19 on a daily base for months and years, it seems 
reasonable to ask for additional molecular and physiological studies to unravel the functional 
impact of possible changes in genetic expression of the host. 
 
5.4 Pathogenicity 
EFSA has recommended the Qualified Presumption of Safety approach in order to assess the 
safety of microbial species (not strains) used in food, and Lactobacillus paracasei has 
achieved the status QPS at species level (EFSA, 2009a). VKM’s Panel on Biological Hazard 
has however commented upon EFSAs QPS-opinion:  
“The decision of whether or not to award QPS status to microorganisms should remain with 
risk assessors, and should be subject to review at pre-determined intervals, as well as 
triggered by specific events, for example if a specific alteration occurs, including acquisition 
of new, relevant knowledge. Furthermore, consideration should be given to whether QPS 
should be applied to microorganisms with respect to particular consumer groups (or whether 
particular, potentially-vulnerable consumer groups should be excluded)” (VKM, 2007). 
 
5.5 Infections 
Infections caused by Lactobacillus are considered extremely uncommon among 
immunocompetent people. The wide distribution of Lactobacillus and the relatively few 
infections they cause indicates that these bacteria have very low virulence in healthy humans. 
This lack of pathogenicity seems to extend across all age groups. EFSA has stressed that 
human infections should remain a topic for surveillance (EFSA, 2009c).   
Lactobacillus infections do occasionally occur, mainly as bacteremia, endocarditis and 
localized infections (e.g. abscesses, peritonitis, meningitis) in patients with severe underlying 
diseases. Most of them are elderly, but children are not excluded. The species most often 
isolated are L. casei and L. rhamnosus, followed by L. paracasei.  
The increasing use of immunosuppressive therapy and broad spectrum antibiotics ineffective 
against Lactobacillus might increase the importance of these bacteria as possible pathogens. 
 
5.6 Benefit 
In order to be able to draw any conclusions regarding beneficial effects of F19, there is a need 
for randomised placebo-controlled studies in larger populations in the relevant age group. 
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5.7 Health claims 
According to EFSA, Lactobacillus paracasei ssp. paracasei  F19 is sufficiently characterized 
(EFSA, 2009c). The documentation provided is however not sufficient to claim positive 
health effects and thus F19 is not proven to be probiotic.  
No documentation is provided which may substantiate the claims on the package or website 
for the relevant products that processed cereal-based baby food fortified with F19 “keeps the 
gut in balance” or “contributes to maintain a healthier and more robust gut flora”.  
It is not the mandate of this report to evaluate the health claims related to the products as these 
health claims are assessed by EFSA. The claimed health effects of the product in question are 
similar to those assessed by EFSA for F19 and other probiotic bacteria. None of the health 
claims pertaining to any strain of probiotic bacteria have so far been accepted by EFSA. In a 
scientific opinion related to F19 and bowel movement function, it was concluded that a cause 
and effect relationship between the consumption of F19 and improvement of bowel 
movement function was not established.  
Incorrect health claims may give the consumers false expectations, and in worst case promote  
excessive use of a product that is not sufficiently documented or proven safe. 
 
5.8 Dose-response studies 
There are no dose-response studies on F19. The response to a probiotic strain depends on both 
the survival of the probiotic through the stomach and duodenum and on the actual efficacy of 
the strain concerned in the intestine. There is no consensus of opinion as to the dose of 
probiotics needed in order to achieve an effect, but some studies suggest 108 cfu viable cells 
per day for adults. The bacterial dose contained in one portion of processed cereal-based food 
is 108 cfu cells, which could arguably be a high dose for small children. Therefore, the number 
of viable cells added to the notified products is presumably not dictated by a documented 
need for a specified dose of viable bacteria in order for a potential health effect to be observed 
in small children. 
 
5.9 Contraindications for use, special groups 
The notifier has applied for 2 cereal-based products containing F19. As the clinical 
documentation is restricted to one group of healthy children receiving one of the products up 
to 13 months of age, there is no data related to F19 mentioning specific groups of children in 
which F19 should be avoided. 
However, based on experience with other probiotics, it is reasonable to underline that F19 
should not be given to immunocompromised or seriously ill children (VKM, 2009). 
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6 Data gaps 
• Dose – response studies on children 
• Studies on genetic stability 
• Studies on adherence to enterocytes and/or mucus “colonisation” 
• Studies focusing on the impact of different deliverance matrixes 
• Double-blind placebo-controlled clinical studies focusing on safety, short- and long 
term. 
• Double-blind placebo-controlled studies on positive health effects in children 1 – 3 
years of age 
• F19, when given as processed cereal-based food containing Lactobacillus paracasei 
ssp. paracasei F19, may switch on/off host genes of physiological importance, and the 
need for further studies are too obvious to be ignored. 
• Correct antimicrobial resistance profile 
• Information regarding type of antimicrobial resistance properties (inherent or 
acquired) 
• Localisation of antimicrobial resistance genes (plasmid or chromosome or both) 
• Presence of mobile genetic elements like Insertion elements (IS), integrons, 
transposons, gene cassettes, etc 
• Before giving Lactobacillus paracasei ssp. paracasei F19 on a daily base for months 
and years, it seems reasonable to ask for additional molecular and physiological 
studies to unravel the functional impact of possible changes in genetic expression of 
the host. 
• Differences in establishment of a normal gut flora should be investigated. Long term 
follow up including clinical parameters is missing. 
• Molecular and physiological studies to unravel the functional impact of possible 
changes in genetic expression of the host 
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7 Answer to the terms of reference 
1. What benefit can children (1 to 3 years) have from consuming processed cereal-based food 
containing Lactobacillus paracasei ssp. paracasei F19? 
There is only one study indicating a positive effect of Lactobacillus paracasei ssp. paracasei 
F19 given to infants 4 – 13 months on the development of eczema.   
The positive health effects claimed for processed cereal-based food containing Lactobacillus 
paracasei ssp. paracasei F19 are not scientifically substantiated. Thus the claims “good for 
gut health”, “strengthens the immune system” or “has a health promoting effect for children 
and adults” are not evidence-based. No conclusions can be drawn as to positive effects from 
F19 in children 1 – 3 years of age. 
 
2. What impact can the addition of Lactobacillus paracasei ssp. paracasei F19 to processed 
cereal-based food for children (1 to 3 years) have on the development of allergy? 
There is no documentation of any effect on the development of allergic sensitization in 
children at 13 months of age, (West et al., 2009) and no other documentation on allergic 
sensitization in children 1 – 3 years having been fed Lactobacillus paracasei ssp. paracasei 
F19 have been provided.    
 
3. Are there any contraindications regarding the consumption of processed cereal-based  food 
containing Lactobacillus paracasei ssp. paracasei F19 for children (1 to 3 years)? 
There is no answer to this question due to absence of long term studies in children receiving 
F19 on a daily base.  
 
4. Is there any risk that the consumption of processed cereal-based food containing 
Lactobacillus paracasei ssp. paracasei F19 can lead to a spreading of antimicrobial resistance 
to other members of the gut microbiota? 
This question cannot be answered since information provided by the notifier regarding 
possible association between antimicrobial resistance phenotype and resistance genes is 
insufficient and partly inconsistent. 
In general and in the case of the presence of resistance gene(s) in F19, the risk of transfer of 
such gene(s) to the resident microbiota and pathogenic bacteria and increased development of 
antimicrobial resistance in bacteria can not be excluded. 
 
5. What possible negative health effects are correlated to the daily consumption of processed 
cereal-based food containing Lactobacillus paracasei ssp. paracasei F19? Furthermore, will 
an increased consumption (amount and frequency) result in pronounced effects?  
There are no published dose-response studies of F19 in children, neither regarding survival of 
F19 in the gastrointestinal tract, nor possible negative health effects. Thus the potential for 
negative health effects as e.g. spreading of antimicrobial resistance or unfavorable impact on 
the genetic expression by the host related to the frequency and/or dose of a monoculture of 
F19 cannot be assessed. 
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6. Do the products contain ingredients that can have prebiotic effect?  
Any food products which contain whole grains contain fibre components, some of which may 
not be hydrolyzed by human digestive enzymes. They will therefore pass undigested into the 
colon where they may be metabolised. Such components may stimulate beneficial members 
of the colon flora and could then be considered to have a prebiotic effect. To the best of our 
knowledge, F19 has not been assessed for its ability to metabolise such components.  
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Appendix I. Norwegian terms of reference: 
1. Hvilken nytte kan barn fra 1 inntil 3 år ha av å bruke barnegrøt tilsatt Lactobacillus 
paracasei ssp. paracasei F19? 
2. Hva betyr tilsetning av Lactobacillus paracasei ssp. paracasei F19 i barnegrøt for barn fra 
1 inntil 3 år for utvikling av allergi? 
3. Er det noen kontraindikasjoner ved bruk av barnegrøt som inneholder Lactobacillus 
paracasei ssp. paracasei F19 for barn fra 1 inntil 3 år? 
4. Er det risiko for at bruken av Lactobacillus paracasei ssp. paracasei F19 i barnegrøt kan 
føre til spredning3 av antimikrobiell resistens? 
5. Hvilke eventuelle negative effekter vil bruk av Lactobacillus paracasei ssp. paracasei F19 
(mengde og frekvens) i barnegrøt for barn fra 1 inntil 3 år kunne ha? 
6. Inneholder produktene ingredienser som kan virke som prebiotika? 
 
 
                                                 
 
3
 Overføring av resistensgener til andre tarmbakteriearter 
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Appendix II. Påstander i forslag til merking av produktene på norsk samt tekst fra 
virksomhetens hjemmeside 
 
På pakningene: 
 
Flerkornsgrøt med probiotika (For barn fra 12 måneder) 
 
Sunn mat for små mager. 
 
Probiotika holder magen i balanse. 
 
Flerkornsgrøt med probiotika er tilsatt melkesyrebakterier som naturlig finnes i tarmen vår. Et 
ekstra tilskudd av disse bidrar til å holde magen i balanse, og bedre immunsystemet. 
 
Havregrøt med probiotika (For barn fra 1,5 år) 
 
Havregrøt med probiotika er tilsatt melkesyrebakterier som naturlig finnes i tarmen vår. Et 
ekstra tilskudd av disse bidrar til å holde magen i balanse, og bedre immunsystemet. 
 
På hjemmesiden: 
 
Havregrøt  med banan og bringebær inneholder probiotiske melkesyrebakterier som har 
vitenskapelige dokumenterte egenskaper. Probiotiske melkesyrebakterier finnes naturlig i 
tarmen vår, og et ekstra tilskudd av disse kan bidra til å opprettholde en sunnere og mer 
motstandsdyktig flora. Mage- og tarmsystemet er kroppens viktigste immunsystem og 
probiotika holder magen i balanse.   
 
I barnehagen, og spesielt den første tiden, er det mange barn som blir syke med forkjølelse 
eller får mageproblemer. 
For å hjelpe immunforsvaret til de små, kan det være lurt å gi barna et ekstra tilskudd av 
probiotiske melkesyrebakterier. Probiotika har vist seg å ha en helsefremmende effekt på barn 
og voksne.                          
Mange barn har hatt sitt aller første møte med barnehagen denne høsten. Barnehagestart er en 
viktig og stor hendelse for mange barn. Det er deres første møte med et selvstendig liv uten 
foreldrene til å beskytte seg. Dette er en tid da en skal lære seg å dele leker og ha tålmodighet 
ved matbordet der det er flere mager å mette enn armer til å servere.  
Den første tiden i barnehagen er også møte med mange nye bakterier, samtidig som høstens 
kalde og fuktige vær setter immunforsvaret på prøve.  
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Helt fra spedbarnet forlater det sterile miljøet i livmoren og møter en verden full av bakterier, 
starter etableringen av komplekse bakteriekulturer på hud og slimhinner, som munn, svelg og 
tarmkanalen. Dette kalles "normalflora".  
Bare i tykktarmen kommer mer enn 500 ulike bakteriearter til å etablere seg. Denne prosessen 
skjer suksessivt og en "voksen" tarmflora oppnås ikke før i 3-4 års alderen. Bakteriene i 
tarmfloraen har stor betydning for stimuleringen av vårt immunsystem. De fleste av tarmens 
bakterier er "snille" og gir sjelden eller aldri opphav til infeksjoner.  
En sammensatt tarmflora gir beskyttelse mot kolonisering av farlige bakterier, gjennom å 
skape konkurranse om næringen og plassen. Tarmbakterienes evne til å stimulere 
immunsystemet og konkurrere med farlige bakterier har ført til utviklingen av probiotika.  
Probiotiske melkesyrebakterier er ufarlige bakterier som kan tilsettes mat og drikke. 
Forskning viser at en del probiotika har god effekt på visse infeksjoner og inflammatoriske 
tilstander hos barn.  
Probiotiske bakterier overlever mage- tarmkanalen og "bosetter" seg i tarmen i en periode og 
kan bidra til å opprettholde en sunnere og mer motstandsdyktig flora. Men det er viktig med 
stadig tiførsel, da bakteriene forsvinner hvis det ikke tilføres flere.  
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Appendix IV. Other assessments and opinions on probiotics from VKM and EFSA. 
 
Assessment of benefits and risks of probiotics in processed cereal-based babyfoods. 
Bifidobacterium lactis Bb12 (VKM, 2010). 
The use of probiotics for patients in hospitals. A benefit and risk assessment (Halvorsen et al., 
2009). 
Scientific substantiation of a health claim related to LGG® MAX and reduction of gastro-
intestinal discomfort (EFSA, 2008). 
Scientific substantiation of a health claim related to LACTORAL (a combination of three 
probiotic strains: Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium 
longum) and normal functioning of the alimentary tract (EFSA, 2008). 
Scientific substantiation of a health claim related to regulat®.pro.kid BRAIN and mental and 
cognitive developments of children (EFSA, 2008). 
Scientific substantiation of a health claim related to regulat®.pro.kid IMMUN and immune 
system of children during growth (EFSA, 2008). 
Risk assessment on use of Lactobacillus rhamnosus (LGG) as an ingredient in infant formula 
and baby foods (II) (VKM 2007).  
Risk assessment on use of Lactobacillus rhamnosus (LGG) as an ingredient in infant formula 
and baby foods (VKM 2005). 
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